Panoptix Trifocal Lens in Post Refractive Myopic Laser Vision Correction Surgery

Sponsor
Parkhurst NuVision Clinical Research LLC (Other)
Overall Status
Recruiting
CT.gov ID
NCT04698278
Collaborator
Alcon Research (Industry)
20
Enrollment
1
Location
15.8
Anticipated Duration (Months)
1.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The two main objectives of this study are to demonstrate safety and effectiveness of implanting the PanOptix Trifocal IOL in patients who have had previous myopic Lasik. The primary objectives to demonstrate clinical safety will be the quality of vision questionnaire (QUVID) which will demonstrate the patient's perception of halos, glares, and starbursts before and after the implantation of the trifocal IOL.

The primary objective to demonstrate clinical effectiveness will be done by measuring visual outcomes at distance, intermediate, and near. In addition, the patients will also fill out the spectacle independence questionnaire (IOLSAT Questionnaire) to determine their level of glasses independence postoperatively. In addition, at the conclusion of the study the patient will also fill out a patient satisfaction survey.

Condition or DiseaseIntervention/TreatmentPhase
  • Device: PanOptix Trifocal Intraocular Lens

Detailed Description

Clinical Hypothesis:

The rate of bothersome visual symptom items (defined as a very or extremely bothersome visual symptom that impacts daily living under overall condition) for the patients who are post-refractive who receive a PanOptix Trifocal IOL at the time of cataract surgery will be assessed. The bothersome visual symptom items of interest are halos, glare, and starbursts. Patients will also be assessed on level of glasses independence with an assessment of both corrected and uncorrected distance, intermediate, and near vision. Lastly patient satisfaction score will also be determined.

OVERALL STUDY DESIGN This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.

Duration:

6 months; however, any subject that undergoes a lens repositioning procedure due to IOL misalignment, or reports "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months, will be followed through 1 year postoperatively.

Administration:

Surgeons will perform routine small-incision, femtosecond laser assisted, cataract surgery and use the Alcon-recommended implantation systems for lens implantation. Refractive target outcomes will be emmetropia for both eyes.

Visit Schedule:

Subjects will be bilaterally implanted; the second eye is to be implanted within approximately one month after the first-eye surgery.

All subjects will undergo a minimum of 10 visits:
  1. Preoperative for both eyes

  2. Surgical Procedure for each individual eye

  3. 1-day and 1-week visits for each eye

  4. 1-month, 3-month, and 6-month visits for both eyes together

  5. In addition, a 1-year postoperative visit will be required for subjects who undergo a lens repositioning procedure due to IOL misalignment at any time during the study, and for subjects who report "very" or "extreme" overall bother that impacts daily living for any of the 3 defined bothersome visual symptoms (halos, glare, or starbursts) at 6 months.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Post-Approval Study of the Panoptix Trifocal Lens in Patients Who Have Had Post Refractive Myopic Laser Vision Correction Surgery
Actual Study Start Date :
Mar 8, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Surgical Treatment Group

This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.

Device: PanOptix Trifocal Intraocular Lens
This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.

Outcome Measures

Primary Outcome Measures

  1. Quality of vision questionnaire (QUVID) [3 months post surgery]

    Will assess patient complaints of glares, halos and starbursts after implantation of the trifocal PanOptix lens. Each of these three symptoms will be assessed on how often they occur, severity of each symptom, and how bothersome they are for the patient. The patient will rank the how often they occur as never, rarely, sometimes, most of the time, and always. The patient will rank severity of their worst experience as: none, a little, mild, moderate, and severe. And the patient will rank how bothered they are by each of these symptoms as: not bothered at all, bothered a little bit, bothered somewhat, bothered quite a bit, or bothered very much.

  2. Quality of vision questionnaire (QUVID) [6 months post surgery]

    Will assess patient complaints of glares, halos and starbursts after implantation of the trifocal PanOptix lens. Each of these three symptoms will be assessed on how often they occur, severity of each symptom, and how bothersome they are for the patient. The patient will rank the how often they occur as never, rarely, sometimes, most of the time, and always. The patient will rank severity of their worst experience as: none, a little, mild, moderate, and severe. And the patient will rank how bothered they are by each of these symptoms as: not bothered at all, bothered a little bit, bothered somewhat, bothered quite a bit, or bothered very much.

  3. Patient Vision Satisfaction Survey [3 months post surgery]

    Will look at the level of patient satisfaction with their overall visual quality. Patient will be asked to grade their visual satisfaction as being very satisfied, satisfied, neither satisfied nor dissatisfied, or dissatisfied.

  4. Patient Vision Satisfaction Survey [6 months post surgery]

    Will look at the level of patient satisfaction with their overall visual quality. Patient will be asked to grade their visual satisfaction as being very satisfied, satisfied, neither satisfied nor dissatisfied, or dissatisfied.

  5. Spectacle Independence Questionnaire (IOLSAT Questionnaire) [3 months post surgery]

    Will look at the level of spectacle independence in patients who receive the trifocal PanOptix IOL for their cataracts. Patients will be asked how often they need to wear glasses for near, intermediate, and distant activities in both dim and bright lighting conditions. These will be graded as rarely, sometimes, most of the time, and all the time. Patients will also be asked to characterize their overall visual quality without glasses at near, intermediate, and distant activities in dim and bright lighting conditions. Patients will rank these as: very poor, poor, fair, good, or very good.

  6. Spectacle Independence Questionnaire (IOLSAT Questionnaire) [6 months post surgery]

    Will look at the level of spectacle independence in patients who receive the trifocal PanOptix IOL for their cataracts. Patients will be asked how often they need to wear glasses for near, intermediate, and distant activities in both dim and bright lighting conditions. These will be graded as rarely, sometimes, most of the time, and all the time. Patients will also be asked to characterize their overall visual quality without glasses at near, intermediate, and distant activities in dim and bright lighting conditions. Patients will rank these as: very poor, poor, fair, good, or very good.

  7. Mean photopic monocular and binocular best corrected and uncorrected visual acuity at distance (6 meters), intermediate (60 cm), and near (40 cm). [3 months post surgery]

    Will assess vision at these 3 focal points

  8. Mean photopic monocular and binocular best corrected and uncorrected visual acuity at distance (6 meters), intermediate (60 cm), and near (40 cm). [6 months post surgery]

    Will assess vision at these 3 focal points

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Adults, 22 years of age or older at the time of surgery, diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision

  2. Previous myopic Lasik with a well centered optical zone, corneal higher-order aberrations less than 0.6 um for a 4 mm pupil (measured by iTrace), and a minimum keratometric reading of 35.0 D.

  3. Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures

  4. Best Corrected Distance Visual Acuity (BCDVA) projected to be 0.2 logMAR (Minimum Angle of Resolution) or better

  5. Calculated lens power within the available range

  6. Preoperative keratometric astigmatism at or less than 2.5 D in both operative eyes

  7. Clear intraocular media other than cataract in both eyes

Exclusion Criteria:
  1. Clinically significant corneal abnormalities including corneal dystrophy, irregularity, inflammation or edema.

  2. Previous intraocular surgery other than myopic Lasik

  3. History of or current retinal conditions or predisposition to retinal conditions

  4. Amblyopia

  5. Rubella, congenital, traumatic, or complicated cataracts

  6. History of or current anterior or posterior segment inflammation of any etiology

  7. Iris neovascularization

  8. Glaucoma (uncontrolled or controlled with medication)

  9. Optic nerve atrophy

  10. Subjects with diagnosed degenerative eye disorders

  11. Pregnancy or lactation

  12. Any disease or pathology, other than cataract, that is expected to reduce the potential postoperative BCDVA to a level worse than 0.30 logMAR.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Parkhurst NuVisionSan AntonioTexasUnited States78229

Sponsors and Collaborators

  • Parkhurst NuVision Clinical Research LLC
  • Alcon Research

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brett Mueller, Principal Investigator, Parkhurst NuVision Clinical Research LLC
ClinicalTrials.gov Identifier:
NCT04698278
Other Study ID Numbers:
  • TFL210
First Posted:
Jan 6, 2021
Last Update Posted:
Mar 17, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2021